{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:09:42Z","timestamp":1795043382925,"version":"4.10.2"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The occurrence and development of non-small cell lung cancer (NSCLC) are closely related to the immune status of the tumor-host. The immunosuppression caused by tumor cells and toxic side effects produced by chemotherapeutic drugs results in a decrease in immune function, ultimately leading to the failure of clinical chemotherapy treatment. Ginsenoside Rg3 has been clinically reported to have positive effects in enhancing immune function in patients. Thus, we screened and evaluated the quality of the evidence regarding the benefits of ginsenoside Rg3 and conducted a meta-analysis to assess the impact on improving immune function in NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The PubMed, EMBASE, Cochrane Library, CNKI, Weipu (VIP), and Wanfang databases were searched in this study, all from the time of library construction to January 2023.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total,12 trials with a sample size of 1008 cases were included based on the eligible criteria. The results showed that compared with first-line chemotherapy alone, the combination of ginsenoside Rg3 and first-line chemotherapy could better improve level of the CD3<jats:sup>+<\/jats:sup> T lymphocytes [mean difference (MD) = 4.72; 95% confidence intervals (CI): 3.92, 5.53; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .00001], CD4<jats:sup>+<\/jats:sup> T lymphocytes (MD = 4.93; 95% CI: 4.61, 5.26; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .00001), CD8<jats:sup>+<\/jats:sup> T lymphocytes (MD = 2.67; 95% CI: 0.93, 4.37; <jats:italic toggle=\"yes\">P<\/jats:italic> = .003), CD4<jats:sup>+<\/jats:sup>\/CD8<jats:sup>+<\/jats:sup> T lymphocytes (MD = 0.20; 95% CI: 0.09, 0.32; <jats:italic toggle=\"yes\">P<\/jats:italic> = .0006), increase the activity of nature killer cells (MD = 2.11; 95% CI: 0.58, 3.63; <jats:italic toggle=\"yes\">P<\/jats:italic> = .007), recover the decline of the white blood cell count induced by chemotherapy, and improve the clinical efficacy for patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study confirmed that ginsenoside Rg3 has some efficacy advantages for improving immune function in patients with NSCLC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033463","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T13:18:37Z","timestamp":1680873517000},"page":"e33463","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["The effect of ginsenoside Rg3 combined with chemotherapy on immune function in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"102","author":[{"given":"Song","family":"Gao","sequence":"first","affiliation":[{"name":"Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application; Anhui University of Chinese Medicine, Hefei, Anhui, China"},{"name":"MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials; Key Laboratory of Xin\u2019an Medicine (Anhui University of Chinese Medicine), The Ministry of Education, Anhui Province Key Laboratory of Chinese Medicinal Formula; Plant Active Peptide Function Food Innovative Manufacturing Industry Innovation Team, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cancan","family":"Fang","sequence":"additional","affiliation":[{"name":"Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application; Anhui University of Chinese Medicine, Hefei, Anhui, China"},{"name":"MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials; Key Laboratory of Xin\u2019an Medicine (Anhui University of Chinese Medicine), The Ministry of Education, Anhui Province Key Laboratory of Chinese Medicinal Formula; Plant Active Peptide Function Food Innovative Manufacturing Industry Innovation Team, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application; Anhui University of Chinese Medicine, Hefei, Anhui, China"},{"name":"MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials; Key Laboratory of Xin\u2019an Medicine (Anhui University of Chinese Medicine), The Ministry of Education, Anhui Province Key Laboratory of Chinese Medicinal Formula; Plant Active Peptide Function Food Innovative Manufacturing Industry Innovation Team, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application; Anhui University of Chinese Medicine, Hefei, Anhui, China"},{"name":"MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials; Key Laboratory of Xin\u2019an Medicine (Anhui University of Chinese Medicine), The Ministry of Education, Anhui Province Key Laboratory of Chinese Medicinal Formula; Plant Active Peptide Function Food Innovative Manufacturing Industry Innovation Team, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application; Anhui University of Chinese Medicine, Hefei, Anhui, China"},{"name":"MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials; Key Laboratory of Xin\u2019an Medicine (Anhui University of Chinese Medicine), The Ministry of Education, Anhui Province Key Laboratory of Chinese Medicinal Formula; Plant Active Peptide Function Food Innovative Manufacturing Industry Innovation Team, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyou","family":"Fang","sequence":"additional","affiliation":[{"name":"Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application; Anhui University of Chinese Medicine, Hefei, Anhui, China"},{"name":"MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials; Key Laboratory of Xin\u2019an Medicine (Anhui University of Chinese Medicine), The Ministry of Education, Anhui Province Key Laboratory of Chinese Medicinal Formula; Plant Active Peptide Function Food Innovative Manufacturing Industry Innovation Team, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[{"name":"Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1125-2505","authenticated-orcid":false,"given":"Rongfeng","family":"Hu","sequence":"additional","affiliation":[{"name":"Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application; Anhui University of Chinese Medicine, Hefei, Anhui, China"},{"name":"MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials; Key Laboratory of Xin\u2019an Medicine (Anhui University of Chinese Medicine), The Ministry of Education, Anhui Province Key Laboratory of Chinese Medicinal Formula; Plant Active Peptide Function Food Innovative Manufacturing Industry Innovation Team, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00262-020-02752-z","article-title":"Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.","volume":"70","author":"Brozos-V\u00e1zquez","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer.","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00262-019-02310-2","article-title":"Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.","volume":"68","author":"Nadal","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression.","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer.","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1634\/theoncologist.2019-0570","article-title":"Antibacterial use is associated with an increased risk of hematologic and gastrointestinal adverse events in patients treated with gemcitabine for stage IV pancreatic cancer.","volume":"25","author":"Corty","year":"2020","journal-title":"Oncologist"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3892\/ijmm.2017.2857","article-title":"Anticancer effects of ginsenoside Rg3 (Review).","volume":"39","author":"Sun","year":"2017","journal-title":"Int J Mol Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"10680","DOI":"10.1002\/jcp.27731","article-title":"Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-\u03baB- and HIF-1\u03b1-mediated downregulation of PTX3.","volume":"234","author":"Ahmmed","year":"2019","journal-title":"J Cell Physiol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.3390\/molecules25214905","article-title":"Anti-angiogenic properties of ginsenoside Rg3.","volume":"25","author":"Nakhjavani","year":"2020","journal-title":"Molecules"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2017.11.037","article-title":"Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-\u03baB mediated epithelial\u2013mesenchymal transition and stemness.","volume":"415","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jconrel.2020.12.036","article-title":"Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy.","volume":"330","author":"Zhu","year":"2021","journal-title":"J Control Release"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"eabj1262","DOI":"10.1126\/sciadv.abj1262","article-title":"Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches.","volume":"8","author":"Xia","year":"2022","journal-title":"Sci Adv"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.arthro.2014.11.014","article-title":"Does double-bundle anterior cruciate ligament reconstruction improve postoperative knee stability compared with single-bundle techniques? A systematic review of overlapping meta-analyses.","volume":"31","author":"Mascarenhas","year":"2015","journal-title":"Arthroscopy"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.arthro.2014.03.015","article-title":"Is double-row rotator cuff repair clinically superior to single-row rotator cuff repair: a systematic review of overlapping meta-analyses.","volume":"30","author":"Mascarenhas","year":"2014","journal-title":"Arthroscopy"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2021","journal-title":"BMJ"},{"key":"R18-20250504","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions.","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20250504","first-page":"1012","article-title":"Analysis of the effect of senyi capsule on clinical chemotheraoy effect and immune function in advance non-small cell lung cancer.","volume":"34","author":"Yu","year":"2018","journal-title":"Chin J Immunol"},{"key":"R20-20250504","first-page":"779","article-title":"Effects of combined Chinese and Western medicine on quality of life and immune function in patients with advanced lung cancer.","volume":"28","author":"Hou","year":"2013","journal-title":"J Chin Med"},{"key":"R21-20250504","first-page":"847","article-title":"Clinical observation on the treatment of advanced non-small cell lung cancer with Ganyi capsule combined with NP regimen.","volume":"12","author":"Liu","year":"2007","journal-title":"J Clin Oncol"},{"key":"R22-20250504","first-page":"554","article-title":"Clinical observation of advanced non-small cell lung cancer treated by adjuvant chemotherapy with Ganyi capsule.","volume":"36","author":"Liu","year":"2007","journal-title":"Shanxi Med Mag"},{"key":"R23-20250504","first-page":"186","article-title":"Effects of ginsenoside Rg3 capsules on serum TGF-\u03b21, VEGF and immune function in patients with non-small cell lung cancer.","volume":"41","author":"Shi","year":"2018","journal-title":"Heilongjiang Pharm Sci"},{"key":"R24-20250504","first-page":"43","article-title":"Clinical effects of gangyi capsule maintenance treatment for advanced non-small cell lung cancer.","volume":"8","author":"Shi","year":"2015","journal-title":"J Clin Ration Drug Use"},{"key":"R25-20250504","first-page":"133","article-title":"A clinical study on the treatment of advanced non-small cell lung cancer with gangyi capsule combined with hydroxycamptothecin and cisplatin.","volume":"35","author":"Kang","year":"2020","journal-title":"Mod Drugs Clin"},{"key":"R26-20250504","first-page":"1649","article-title":"Analysis of the efficacy of Senyi capsules in patients with advanced non-small cell lung cancer based on gemcitabine combined with cisplatin chemotherapy regimen.","volume":"26","author":"Zhang","year":"2020","journal-title":"Chin J Basic Chin Med"},{"key":"R27-20250504","first-page":"52","article-title":"Summary of the phase II clinical trial of Ganyi capsule for lung cancer.","volume":"29","author":"Lin","year":"2002","journal-title":"China Clin Oncol"},{"key":"R28-20250504","first-page":"2","article-title":"Effect of senyi capsule on the chemotherapy effect of patients with advanced non-small cell lung cancer.","volume":"36","author":"Pan","year":"2019","journal-title":"Med Clin Res"},{"key":"R29-20250504","first-page":"34","article-title":"The effect of Sengyi capsule on peripheral lymphocyte phenotype of non-small cell lung cancer and its mechanism.","volume":"36","author":"Wang","year":"2015","journal-title":"Yunnan J Tradit Chin Med"},{"key":"R30-20250504","first-page":"229","article-title":"Clinical observation of ginsenoside Rg3 combined with chemotherapy in the postoperative adjuvant treatment of non-small cell lung cancer in the elderly.","volume":"28","author":"Jin","year":"2011","journal-title":"J Xinxiang Med Coll"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy.","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.it.2021.09.002","article-title":"Metabolic regulation of the cancer-immunity cycle.","volume":"42","author":"Somarribas Patterson","year":"2021","journal-title":"Trends Immunol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.biopha.2017.09.129","article-title":"Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.","volume":"96","author":"Jiang","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3390\/molecules25092068","article-title":"Inhibition of programmed death receptor-1\/programmed death ligand-1 interactions by ginsenoside metabolites.","volume":"25","author":"Yim","year":"2020","journal-title":"Molecules"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2021.06.005","article-title":"A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer.","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jep.2019.03.031","article-title":"Korean Red ginseng extract inhibits glioblastoma propagation by blocking the Wnt signaling pathway.","volume":"236","author":"Ham","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"R37-20250504","first-page":"127","article-title":"Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.","volume":"52","author":"Tang","year":"2018","journal-title":"Int J Oncol"},{"key":"R38-20250504","first-page":"2296","article-title":"Effects of Ganyi capsule combined with chemotherapy on the recent efficacy and serum NKG2D, IFN-\u03b3, IL-2 levels and T lymphocyte subsets in patients with intermediate to advanced non-small cell lung cancer.","volume":"40","author":"Zhang","year":"2020","journal-title":"Chin J Gerontol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"e31307","DOI":"10.1097\/MD.0000000000031307","article-title":"T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer.","volume":"101","author":"Chen","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"816005","DOI":"10.3389\/fimmu.2022.816005","article-title":"CD3+CD4-CD8- (Double-Negative) T cells in inflammation, immune disorders and cancer.","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-20-2891","article-title":"Circulating tumor cell subtypes and T-cell populations as prognostic biomarkers to combination immunotherapy in patients with metastatic genitourinary cancer.","volume":"27","author":"Chalfin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R42-20250504","first-page":"1211","article-title":"Effect of ginsenoside Rg3 on CD 80\/86 expression and cellular immune function in patients undergoing radiotherapy for nasopharyngeal carcinoma.","volume":"37","author":"Chen","year":"2017","journal-title":"Jilin Chin Med"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-infiltrating natural killer cells.","volume":"11","author":"C\u00f3zar","year":"2021","journal-title":"Cancer Discov"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"108618","DOI":"10.1016\/j.intimp.2022.108618","article-title":"Ginsenoside 20(R)-Rg3 enhances natural killer cell activity by increasing activating receptor expression through the MAPK\/ERK signaling pathway.","volume":"107","author":"Lee","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1097\/SLA.0000000000004564","article-title":"Multicenter randomized phase 2 trial comparing chemoradiotherapy and docetaxel plus 5-fluorouracil and cisplatin chemotherapy as initial induction therapy for subsequent conversion surgery in patients with clinical T4b esophageal cancer: short-term results.","volume":"274","author":"Sugimura","year":"2021","journal-title":"Ann Surg"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1039\/D0FO03341C","article-title":"Efficacy of ginseng and its ingredients as adjuvants to chemotherapy in non-small cell lung cancer.","volume":"12","author":"Zhu","year":"2021","journal-title":"Food Funct"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1142\/S0192415X2150035X","article-title":"20(S)-Ginsenoside Rg3 inhibits lung cancer cell proliferation by targeting EGFR-mediated Ras\/Raf\/MEK\/ERK pathway.","volume":"49","author":"Liang","year":"2021","journal-title":"Am J Chin Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:26:21Z","timestamp":1746325581000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":47,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033463","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}